| URL | https://www.supplychaindive.com/news/novartis-23-b |
| Source | supply chain dive |
| Date Published | 04/11/2025 |
| Author Name | Jonathan Gardner |
| Company/Division name | Novartis |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2025 |
| Year reshoring implemented or to be implemented: | 2030 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 23 |
| Country(ies) from which reshored: | Switzerland |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharmaceuticals |
| What non-domestic negative factors made offshoring less attractive? | Tariffs |